Computational Drug Repurposing

Single-cell genomics.
Novel therapeutics.
50 patent-pending pipelines.

Ritschel Research applies single-cell RNA-seq analysis to publicly available human tissue datasets, identifying disease-specific drug-target candidate pairs at single-cell resolution across autoimmune disease, neurodegeneration, oncology, and fibrosis. The anchor program is a scleroderma and CREST-spectrum cluster developed with LINCS signature-reversal analysis.

Discuss Licensing

Portfolio Coverage

Disease-specific single-cell analyses across six categories.

Autoimmune & Inflammatory

SLE · RA · IBD · MS · Sjögren's · Psoriasis · AD · CREST subtypes

Neurodegeneration

Alzheimer's · Parkinson's · ALS · Huntington's · FTD

Pulmonary & Fibrotic

Scleroderma · IPF · COPD · Asthma

GI & Metabolic

MASH · T1D · T2D · Endometriosis · EoE · IBD

Oncology

Glioblastoma · Gastric Premalignant

Additional Indications

Long COVID · CKD · Migraine · Sarcoidosis · Inflammaging

View Full Patent Registry →

Methodology

Reproducible. Fully archived.

scRNA-seq Input

NCBI GEO public
datasets

scVI Batch Correction

GPU-accelerated
integration

Leiden Clustering

Cell-type-specific
resolution

Wilcoxon DE

Top DE genes
per cluster

ChEMBL Screen

pChEMBL ≥7.5
bioactivity filter

Novelty Filter

PubChem patent
classification

Ranked Output

Scored candidates
+ watchlist

All 50 patent specifications archived on Zenodo (CC BY 4.0) with permanent DOIs. All GEO datasets publicly available and independently reproducible. Sole inventor: Glen Charles Ritschel. Priority dates: February–April 2026.

Pipeline Validation

Independent preclinical corroboration in scleroderma. The portfolio's most developed work centers on a scleroderma and CREST-spectrum cluster, where candidate selection converges on the c-Abl/SRC and MEK/ERK axes in fibrosis. Independent preclinical work (Wermuth & Jimenez, PLoS One 2018) reported that bosutinib, a c-Abl/SRC inhibitor, produced dose-dependent reduction of dermal and pulmonary fibrosis and reversed the profibrotic myofibroblast gene-expression signature. This is independent work reaching a convergent conclusion about the same biology, not a claim of clinical efficacy.

Read the Independent Study →

Licensing & Partnership

Seeking option or license agreement with buyer-funded non-provisional conversion.

Full portfolio exclusivity and therapeutic-area carve-outs are available. Priority dates expire February–April 2027. One coordinated diligence cycle covers all 50 patents simultaneously — the Zenodo archive is your data room, available now.

Inventor

Glen Charles Ritschel

Organization

Ritschel Research, Tega Cay SC

[email protected]

Single-cell genomics.Novel therapeutics.50 patent-pending pipelines.